iOnctura commences randomized Phase II study in metastatic uveal melanoma
First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ
The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment of uveal melanoma – benefits include 10 years market exclusivity in the European Union
Geneva, Switzerland and Amsterdam, The Netherlands, 20 March 2025 – iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye.
